Chiral stability study of oral liquid clopidogrel formulations for infants

Journal of Pharmacy Practice and Research

Volumn 42, Issue 2, 2012, Pages 106-110

  Mihaila, Bianca ^a   Ellis, David ^b   Rozek, Thomas ^c   Milne, Robert ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CLOPIDOGREL; DRUG VEHICLE; FLAVORING AGENT; GLYCEROL; ORA PLUS; ORA SWEET; PLACEBO; PROPYLENE GLYCOL; SACCHARIN SODIUM; SOLVENT; SUSPENDING AGENT; UNCLASSIFIED DRUG;

ARTICLE; CHIRAL CHROMATOGRAPHY; CHIRALITY; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; FREEZING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID; ROOM TEMPERATURE; SHELF LIFE; STORAGE TEMPERATURE; SUSPENSION; SYRUP; THERMOSTABILITY;

EID: 84864381904     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2012.tb00144.x     Document Type: Article

References (18)

1. Li JS, Yow E, Berezny KY, Bokesch PM, Takahashi M, Graham TP Jr, et al. Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) Trial. Circulation 2008; 117: 553-9.
2. Li JS, Newburger JW. Antiplatelet therapy in pediatric cardiovascular patients. Pediatr Cardiol 2010; 31: 454-61.
3. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92-9.
4. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel-clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-16.
5. Patrono C, Baigent C, Hirsh J, Roth G; American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (suppl 6): 199S-233S.
6. Sanofi-Synthelabo v. Apotex Inc., 492 F Suppl 2 353 (Fed Cir, 2006). Available from .
7. Durga Rao D, Kalyanaraman L, Sait SS, Venkata Rao P. A validated stabilityindicating normal phase LC method for clopidogrel bisulfate and its impurities in bulk drug and pharmaceutical dosage form. J Pharm Biomed Anal 2010; 52: 160-5.
8. Gomez Y, Adams E, Hoogmartens J. Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand. J Pharm Biomed Anal 2004; 34: 341-8.
9. Reist M, Roy-De Vos M, Montseny JP, Mayer JM, Carrupt PA, Berger Y, et al. Very slow chiral inversion of clopidogrel in rats: A pharmacokinetic and mechanistic investigation. Drug Metab Dispos 2000; 28: 1405-10.
10. British Pharmacopoeia Commission. British pharmacopoeia 2010. Part II characteristics: solubilities. London: The Stationery Office; 2009. Available from .
11. Plavix (clopidogrel) Australian approved product information. Sydney: Sanofi-Aventis Australia; 2009.
12. Skillman KL, Caruthers RL, Johnson CE. Stability of an extemporaneously prepared clopidogrel oral suspension. Am J Health Syst Pharm 2010; 67: 559-61.
13. Jew RK, Soo-Hoo W, Erush SC. Extemporaneous formulations for pediatric, geriatric, and special needs patients. 2nd ed. Maryland: American Society of Health-System Pharmacists; 2010.
14. Lloyd AV. Clopidogrel 5-mg/mL oral suspension. Int J Pharm Comp 2011; 15: 155.
15. Nikolic K, Ivkovic B, Besovic Z, Markovic S, Agbaba D. A validated enantiospecific method for determination and purity assay of clopidogrel. Chirality 2009; 21: 878-85.
16. Accordino A, Chambers R, Thompson B. A short-term stability study of an oral solution of dexamethasone. Aust J Hosp Pharm 1994; 24: 312-16.
17. US Pharmacopeial Convention. US Pharmacopoeia 30: national formulary
18. Rockville: US Pharmacopoeial Convention; 2007.